This hypothesis is also supported by the outcome that CX-4945-treatment reduces diet-induced obesity in mice by promoting whole-body energy expenditure41 and that CK2 is involved in pathways implicated also in adiposopathy as HIF1-driven angiogesis28 and NF-kB-mediated inflammation15. Here, NFKB1 is linked to obesity disorder.